Publication details
Chronická hepatitida B
| Title in English | Chronic hepatitis B |
|---|---|
| Authors | |
| Year of publication | 2015 |
| Type | Article in Periodical |
| Magazine / Source | Postgraduální gastroenterologie & hepatologie |
| MU Faculty or unit | |
| Citation | |
| Field | Epidemiology, infectious diseases and clinical immunology |
| Keywords | hepatitis B; pegylated interferon; tenofovir; entecavir |
| Description | According to qualified estimates, there are 350-400 million people with chronic hepatitis B (HBV) infection worldwide. The Czech Republic is among the countries with a low prevalence of HBV infection. According to latest seroprevalent study, 0.56% of the Czech citizens were chronically infected with HBV in 2001. HBV Infection can lead to serious life-threatening liver damage - fulminant hepatitis, liver cirrhosis and hepatocellular carcinoma (HCC). Acute hepatitis B is in most cases benign disease without necessity of antiviral therapy. Chronic hepatitis B viral infection can be treated with pegylated interferon, tenofovir or entecavir. The goal of treatment is to prolong the length of life and improve its quality by preventing the progression of chronic hepatitis to cirrhosis, cirrhosis decompensation and development of HCC. This goal can be achieved if HBV replication can be suppressed in a sustained manner. Then, the accompanying reduction in histological activity lessens the risk of cirrhosis and decreases the risk of HCC, particularly in non-cirrhotic patients. |